TransCelerate and BioCelerate have launched a new data sharing platform to connect preclinical and clinical information to help better inform clinical trials.
LabCorp signed several partnership deals in the second quarter of 2018 as the company aims to enhance the drug development process and continues to invest in its CRO business.
The MHRA has issued guidance outlining how UK pharma would be affected during the Brexit implementation period, due to be finalised in the Withdrawal Agreement come October.
Iqvia recently announced its second quarter 2018 results, which came in “above the high end” of the company’s expectations at $2.567bn, said CEO Ari Bousbib.
Repeal of the hotly debated medical device tax would free up research and development resources and bring clinical trials back to the US, say CRO industry executives.
Novo Nordisk announced a distribution agreement that will see quats delivered by Signet to the healthcare industry in India, as well as Bangladesh and Sri Lanka.
LEO Pharma acquires Bayer’s prescription dermatology unit in a definitive agreement, in hopes of reaching their goal of being the leading global dermatology company by 2025.
The global market for in vitro toxicity testing is predicted to reach $8.8bn by 2023 – and demand is expected to increase, driven by new technologies and regulations, says Charles River.
Accelovance and Linical merged in March of this year to create a global midsized CRO for which ‘future possibilities are endless,’ says newly appointed CEO.
The FDA guidance addresses EHR data use in clinical trials – and while “one of the most prescriptive in recent memory” – does not solve interoperability challenges or address other sources of data, such as wearables.
The EMA has revealed that it is having to cope with “significant staff losses” due to Brexit, which means that it will have to temporarily cut certain activities.
Sanofi has written to the UK’s health secretary and the chief executive of the NHS to inform them that the company is stockpiling drugs ahead of the deadline for Brexit.
The Chinese government has released a notice telling medical institutes to comply with the recall of products containing contaminated valsartan and stop using the medicine.
The Republic of Ireland’s pharmaceutical industry has responded to the Brexit Steering Group’s stance on a withdrawal agreement, which insists the deal include a ‘viable backstop’ for its border with Northern Ireland.
The health and life sciences services provider Ashfield Healthcare Communications, part of UDG Healthcare, is set to open in Manchester, marking the firm’s nine office in the UK.
Less is more as it pertains to data collection in oncology trials, says industry expert, with ePRO use expected to grow significantly over the coming years.
GSK is shutting down its Bangladesh manufacturing plant in an effort to streamline its emerging market operations, laying off 1,000 employees in the process.
The European Commission says it will not intervene in an eviction dispute between a farmer cultivating a “record crop” of goji berry extract for the pharmaceutical industry, and the Romanian government.
The Alliance for Clinical Research Excellence and Safety (ACRES) has released a global quality standard for clinical research sites aimed at increasing data accuracy and integrity.
CTTI’s latest recommendations will help researchers deploy mobile technologies in clinical trials and “pave the way for improving how we develop medicines,” says Pfizer exec.
The multi-year project with an unnamed pharmaceutical company will use the macaque monkey as a developmental model for progressive brain disorders and is valued at more than $1m.
Pfizer has revealed it will invest $5bn to support operations in the US, with the first step being the construction of a 400,000-square-foot production facility, costing $465m.
ACG has expanded its capabilities by completing its work on a lamination facility to be able to complete all packaging requirements for solid oral medication in-house.
Pan-American countries should adopt EMA-style regulations to increase clinical trial transparency and streamline research, according to a recent report.
WCG’s acquisition of KMR Group and MCC addresses sponsor and CRO need to establish a common set of metrics to understand and manage clinical trial performance, says CEO.
The industry needs “to strike a balance” between science and feasible execution as increasingly complex clinical trial protocols are impeding efficiency and driving up costs, says industry expert.
